## Drug Monograph

Drug/Drug Class: **Syndros® (dronabinol) solution /Sympathomimetic Agents**
Prepared for: MO HealthNet
Prepared by: Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

## Executive Summary

| | |
|---|---|
| **Purpose:** | The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use. |
| **Dosage Forms:** | Syndros® is available in an oral solution containing 5 mg dronabinol per ml. |
| **Manufacturer:** | Manufactured by: Renaissance Lakewood LLC, Lakewood, NJ 08701<br>Manufactured for: Insys Therapeutics, Inc., Chandler, AZ 85286 |
| **Indications:** | Syndros® is indicated in adults for the treatment of anorexia associated with weight loss in patients with AIDS and for nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. |
| **Costs:** | $32.43 per ml of Syndros®. Wholesale Acquisition Cost |
| **Summary of Findings:** | MO HealthNet Division recommends Open Access status for this product. |
| **Status Recommendation:** | ☐ Prior Authorization (PA) Required ☒ Open Access<br>☐ Fiscal Edit ☐ PDL |
| **Type of PA Criteria:** | ☐ Increased Risk of ADE ☐ Under Solicitation<br>☐ Appropriate Indications ☒ No PA Required |

Prepared By: Luke Boehmer Pharm.D.
Date: August 30, 2017

© 2017 Conduent Business Services, LLC All Rights Reserved.